European Notebook: Tax Inversions; Patent Settlement Fines; Delays To Release of Clinical Data

The pursuit of mid-sized European pharma by U.S. firms for tax as well as other benefits continued in July, while biotechs in the region stayed cautious about IPOs; the European Commission encountered opposition to its stance on patent settlements, while EMA had to delay starting the pro-active release of clinical trial data.